NF-kB2 Gene Detection for Proteasome Inhibitor Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Not all patients respond to proteasome inhibitors for cancer treatment, and the underlying mechanism for this variability is not well understood, particularly regarding the NF-κB2 gene and its role in responsiveness to these inhibitors.
Innovation Solution
Detecting the presence, truncation, or translocation of the NF-κB2 gene in cancer patients to determine their responsiveness to proteasome inhibitors, and administering effective amounts of proteasome inhibitors or alternative agents like immunomodulators or DNA damaging agents based on these genetic markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If proteasome inhibitors are administered to all cancer patients, then treatment coverage is maximized, but treatment effectiveness decreases due to lack of responsiveness in some patients
Solution Approach 1:
The patent performs preliminary genetic testing to detect the NF-κB2 gene 3' end sequence before administering proteasome inhibitors. This preliminary action identifies patients who are likely to respond to treatment, allowing for selective administration to only those patients, thereby improving treatment effectiveness and reducing waste in non-responders.
Solution Approach 2:
The patent uses the presence or absence of the NF-κB2 gene 3' end sequence as a biomarker parameter to stratify patients into different treatment groups. By changing the approach from uniform treatment to stratified treatment based on this genetic parameter, the patent improves treatment responsiveness and effectiveness.
2Reliability
If genetic testing for NF-κB2 is performed to identify responsive patients, then treatment responsiveness is improved, but testing complexity and cost increase
Solution Approach 1:
The patent extracts and focuses on a specific, critical region of the NF-κB2 gene (the 3' end sequence) for testing, rather than performing comprehensive genomic analysis. This extraction approach simplifies the testing process while maintaining sufficient accuracy to predict treatment responsiveness, thereby reducing testing complexity and cost.
Solution Approach 2:
The patent uses the NF-κB2 gene 3' end sequence as an intermediary biomarker that indirectly predicts treatment responsiveness. This intermediary approach provides a simple, direct test result that can be used for treatment decision-making without requiring complex multi-parameter analysis or multiple tests.
3Ease of operation
If proteasome inhibitors are administered without genetic screening, then treatment administration is simplified, but resource waste increases due to ineffective treatment in non-responders
Solution Approach 1:
The patent performs a simple preliminary genetic test before treatment administration to identify suitable candidates. This preliminary action filters out non-responders before treatment begins, preventing resource waste on ineffective treatments while maintaining ease of operation through a straightforward testing and treatment protocol.
Solution Approach 2:
The patent changes the approach from blind treatment administration to parameter-guided administration based on the NF-κB2 gene 3' end sequence status. This parameter-based stratification ensures resources are allocated to patients who will benefit, reducing waste while keeping the process simple and operationally easy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are methods for selecting use of proteasome inhibitors.